22 December 2023
An endocrinologist says MOF rejected MOH's proposal to procure more SGLT2 inhibitors, which lower blood sugar, because it costs RM800 million to treat 500,000 people in five years, despite RM100 million in savings by cutting hospitalisations and dialysis.